MAIA Biotech Activates First U.S. Site for Phase 2 THIO-101 Trial

MAIA Biotechnology has activated its first U.S. clinical site for the Phase 2 THIO-101 expansion trial, evaluating its lead investigational therapy for third-line non-small cell lung cancer (NSCLC). This expansion aims to reach an estimated 50,000 U.S. patients annually who are resistant to current treatments. The U.S. trial is supported by a $2.3 million NIH grant, building on previous positive efficacy data from 2025, which showed overall survival beyond two years for eight patients.